GlassScriptPhysician profile
Kasem Charnvitayapong
NPI 1497847206
$10,324.88
in general payments reported to CMS, 2019-2025
39 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,947 · 2020: $1,236 · 2021: $2,277 · 2022: $1,537 · 2023: $1,722 · 2024: $398 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.76 |
| Education | $112.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,229.09 | 2019-2025 | Breztri, Fasenra, Symbicort |
| Actelion Pharmaceuticals US, INC. | $1,073.12 | 2019-2024 | Opsumit, Uptravi |
| Philips North America LLC | $989.18 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $872.16 | 2019-2025 | Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $848.57 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $749.37 | 2019-2025 | Arikayce, Brinsupri |
| Olympus Corporation of The Americas | $596.57 | 2019 | |
| Grifols USA, LLC | $541.50 | 2019-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $447.24 | 2019-2024 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $290.81 | 2021-2024 | Glassia, Hyqvia |
| Mallinckrodt Hospital Products INC. | $290.80 | 2021-2024 | Acthar |
| Mylan Specialty L.P. | $271.13 | 2019-2023 | Yupelri |
| Pulmonx Corporation | $258.19 | 2021-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Mallinckrodt Enterprises LLC | $250.05 | 2019 | |
| Genentech USA, INC. | $204.07 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasem Charnvitayapong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.